Venker Eric
Reporting owner on Forms 3, 4 and 5, CIK 1801917.
Venker Eric reported on 2 issuers in 2 filings, the latest a Form 4 filed 2026-10-05.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| Roivant Sciences Ltd. CIK 1635088 | officer (President & Immunovant CEO) | 1 | 2026-10-02 |
| Immunovant, Inc. CIK 1764013 | director, officer (Chief Executive Officer) | 1 | 2026-10-05 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| Immunovant, Inc. Common Stock | 2026-10-02 | S sold | -3,506 | $34.11 | 257,075 | Form 4 |
| Immunovant, Inc. Common Stock | 2026-10-01 | M exercised | +92,187 | $14.46 | 346,467 | Form 4 |
| Immunovant, Inc. Common Stock | 2026-10-01 | D returned to the issuer | -85,886 | $33.65 | 260,581 | Form 4 |
| Immunovant, Inc. Capped Value Appreciation Rights, derivative | 2026-10-01 | M exercised | -92,187 | $0 | 921,875 | Form 4 |
| Roivant Sciences Ltd. Common Shares | 2026-09-30 | M exercised | +200,000 | $3.85 | 1,799,154 | Form 4 |
| Roivant Sciences Ltd. Common Shares | 2026-09-30 | S sold | -200,000 | $36.62 | 1,599,154 | Form 4 |
| Roivant Sciences Ltd. Stock Option (Right to Buy), derivative | 2026-09-30 | M exercised | -200,000 | $0 | 3,644,834 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001764013-26-000110 | Immunovant, Inc. | 2026-10-05 | ||
| Form 4 0001635088-26-000108 | Roivant Sciences Ltd. | 2026-10-02 |